Biotech | April 06, 2022
Singlera Genomics announces research collaboration with Astellas Pharma
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
The aim is to pursue methylation-based tools to better understand biological reactions to pharmaceuticals
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
According to IQVIA sales data for the 12-month period ending June 2025, the Mycamine for Injection, 50 mg/vial and 100 mg/vial market achieved annual sales of approximately $60.7 million
Xtandi is approved in over 80 countries, including the U.S., EU, and Japan
Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30%
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
Lupin updates on shipment of Mirabegron ER Tablets
Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of US$ 1,019 million in the US
If approved, enfortumab vedotin with KEYTRUDA would be the first combination in China to offer an alternative to chemotherapy
Subscribe To Our Newsletter & Stay Updated
